123 related articles for article (PubMed ID: 29708622)
1. Evaluation of tacrolimus-related CYP3A5 genotyping in China: Results from the First External Quality Assessment Exercise.
Lin G; Zhang X; Zhang K; Han Y; Tan L; Li J
J Clin Lab Anal; 2018 Oct; 32(8):e22563. PubMed ID: 29708622
[TBL] [Abstract][Full Text] [Related]
2. CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients.
Hesselink DA; van Schaik RH; van Agteren M; de Fijter JW; Hartmann A; Zeier M; Budde K; Kuypers DR; Pisarski P; Le Meur Y; Mamelok RD; van Gelder T
Pharmacogenet Genomics; 2008 Apr; 18(4):339-48. PubMed ID: 18334918
[TBL] [Abstract][Full Text] [Related]
3. Impact of cytochrome P450 3A5 polymorphism in graft livers on the frequency of acute cellular rejection in living-donor liver transplantation.
Uesugi M; Kikuchi M; Shinke H; Omura T; Yonezawa A; Matsubara K; Fujimoto Y; Okamoto S; Kaido T; Uemoto S; Masuda S
Pharmacogenet Genomics; 2014 Jul; 24(7):356-66. PubMed ID: 24911663
[TBL] [Abstract][Full Text] [Related]
4. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea.
Jun KR; Lee W; Jang MS; Chun S; Song GW; Park KT; Lee SG; Han DJ; Kang C; Cho DY; Kim JQ; Min WK
Transplantation; 2009 Apr; 87(8):1225-31. PubMed ID: 19384171
[TBL] [Abstract][Full Text] [Related]
5. A randomized clinical trial of age and genotype-guided tacrolimus dosing after pediatric solid organ transplantation.
Min S; Papaz T; Lafreniere-Roula M; Nalli N; Grasemann H; Schwartz SM; Kamath BM; Ng V; Parekh RS; Manlhiot C; Mital S
Pediatr Transplant; 2018 Nov; 22(7):e13285. PubMed ID: 30178515
[TBL] [Abstract][Full Text] [Related]
6. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
Staatz CE; Goodman LK; Tett SE
Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
[TBL] [Abstract][Full Text] [Related]
7. Personalized tacrolimus doses determined by CYP3A5 genotype for induction and maintenance phases of kidney transplantation.
Vannaprasaht S; Reungjui S; Supanya D; Sirivongs D; Pongskul C; Avihingsanon Y; Tassaneeyakul W
Clin Ther; 2013 Nov; 35(11):1762-9. PubMed ID: 24120259
[TBL] [Abstract][Full Text] [Related]
8. Influence of
Nakamura T; Fukuda M; Matsukane R; Suetsugu K; Harada N; Yoshizumi T; Egashira N; Mori M; Masuda S
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32225074
[TBL] [Abstract][Full Text] [Related]
9. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.
Quteineh L; Verstuyft C; Furlan V; Durrbach A; Letierce A; Ferlicot S; Taburet AM; Charpentier B; Becquemont L
Basic Clin Pharmacol Toxicol; 2008 Dec; 103(6):546-52. PubMed ID: 19067682
[TBL] [Abstract][Full Text] [Related]
10. Effect of CYP3A5 polymorphism on the pharmacokinetics of tacrolimus and acute rejection in renal transplant recipients: experience at a single centre.
Cheng Y; Li H; Meng Y; Liu H; Yang L; Xu T; Yu J; Zhao N; Liu Y
Int J Clin Pract Suppl; 2015 May; (183):16-22. PubMed ID: 26177012
[TBL] [Abstract][Full Text] [Related]
11. National Prociency Testing Result of CYP2D6*10 Genotyping for Adjuvant Tamoxifen Therapy in China.
Lin G; Zhang K; Yi L; Han Y; Xie J; Li J
PLoS One; 2016; 11(9):e0162361. PubMed ID: 27603206
[TBL] [Abstract][Full Text] [Related]
12. Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis.
Zuo XC; Ng CM; Barrett JS; Luo AJ; Zhang BK; Deng CH; Xi LY; Cheng K; Ming YZ; Yang GP; Pei Q; Zhu LJ; Yuan H; Liao HQ; Ding JJ; Wu D; Zhou YN; Jing NN; Huang ZJ
Pharmacogenet Genomics; 2013 May; 23(5):251-61. PubMed ID: 23459029
[TBL] [Abstract][Full Text] [Related]
13. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.
Deininger KM; Vu A; Page RL; Ambardekar AV; Lindenfeld J; Aquilante CL
Clin Transplant; 2016 Sep; 30(9):1074-81. PubMed ID: 27314545
[TBL] [Abstract][Full Text] [Related]
14. Tacrolimus Dose Optimization Strategy for Refractory Ulcerative Colitis Based on the Cytochrome P450 3A5 Polymorphism Prediction Using Trough Concentration after 24 Hours.
Onodera M; Endo K; Naito T; Moroi R; Kuroha M; Kanazawa Y; Kimura T; Shiga H; Kakuta Y; Negoro K; Kinouchi Y; Shimosegawa T
Digestion; 2018; 97(1):90-96. PubMed ID: 29393157
[TBL] [Abstract][Full Text] [Related]
15. Association Between CYP3A5 Genetic Polymorphisms with Tacrolimus Dose Requirement and Allograft Outcomes in Iranian Kidney Transplant Recipients.
Ghafari S; Dashti-Khavidaki S; Khatami MR; Ghahremani MH; Seyednejad SA; Beh-Pajooh A
Iran J Kidney Dis; 2019 Nov; 13(6):414-416. PubMed ID: 31880588
[TBL] [Abstract][Full Text] [Related]
16. Influence of cytochrome P450 3A5 polymorphisms on viral infection incidence in kidney transplant patients treated with tacrolimus.
Hattori Y; Tanaka H; Teranishi J; Ishida H; Makiyama K; Miyajima E; Noguchi K; Kubota Y
Transplant Proc; 2014; 46(2):570-3. PubMed ID: 24656015
[TBL] [Abstract][Full Text] [Related]
17. Impact of CYP3A5 polymorphism on trough concentrations and outcomes of tacrolimus minimization during the early period after kidney transplantation.
Yaowakulpatana K; Vadcharavivad S; Ingsathit A; Areepium N; Kantachuvesiri S; Phakdeekitcharoen B; Sukasem C; Sra-Ium S; Sumethkul V; Kitiyakara C
Eur J Clin Pharmacol; 2016 Mar; 72(3):277-83. PubMed ID: 26635230
[TBL] [Abstract][Full Text] [Related]
18. Benefits of minimizing immunosuppressive dosage according to cytochrome P450 3A5 genotype in liver transplant patients: findings from a single-center study.
Wang L; Li N; Wang MX; Lu SC
Genet Mol Res; 2015 Apr; 14(2):3191-9. PubMed ID: 25966085
[TBL] [Abstract][Full Text] [Related]
19. CYP3A5 polymorphisms and their effects on tacrolimus exposure in an ethnically diverse South African renal transplant population.
Muller WK; Dandara C; Manning K; Mhandire D; Ensor J; Barday Z; Freercks R
S Afr Med J; 2020 Jan; 110(2):159-166. PubMed ID: 32657689
[TBL] [Abstract][Full Text] [Related]
20. Molecular Genetics External Quality Assessment Pilot Scheme for Irinotecan-Related UGT1A1 Genotyping in China.
Yi L; Lin G; Zhang K; Wang L; Zhang R; Xie J; Li J
PLoS One; 2016; 11(1):e0148081. PubMed ID: 26820647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
